Abstracts of the 2025 Annual Meeting of the ALEH
More infoMetabolic dysfuntion associated liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), and fibrosis progression is the main prognostic factor. However, clinical predictors of fibrosis remain unclear. Diabetes duration has been suggested as a potencial independent risk factor.
To assess the association between T2DM duration and liver fibrosis estimated by the FIB-4 index and liver stiffness measurement (LSM) in Dominican patients with MASLD.
Materials and MethodsA retrospective cohort study was conducted including 127 adults with MASLD, diagnosed based on hepatic steatosis detected by abdominal ultrasound and coexisting T2DM, following international criteria. Patients were evaluated at a tertiary care center in the Dominican Republic between July 2024 and January 2025.
The FIB-4 was calculated using AST, ALT, platelet count, and age.LSM by transient elastography was available 32 cases. Diabetes duration was extracted from medical records and categorized into five groups (0-5, 6-10, 11-15, 16-20 y >20 years). Spearman correlation assessed associations between diabetes duration, FIB-4, and LSM. Nonparametric test compared fibrosis by duration groups. Significance was set at p<0.05.
ResultsMean age was 56.6 ± 13.9 years; 63 % were women. FIB-4 showed moderate correlation with T2DM duration (ρ=0.26, p=0.005) and age (ρ=0.49, p<0.001). In patient aged 35-65 years, FIB-4 strongly correlated with LSM (ρ=0.77, p<0.001). According to FIB-4 classification, 63.8% were low-risk (<1.3), 32.3% intermediate-risk (1.3-2.67), and 3.9% high-risk (>2.67) for advanced fibrosis.
ConclusionsT2DM duration moderately correlates with FIB-4, especially in mind-aged adults, supporting its role in fibrosis risk models.
